达比加群酯对非瓣膜性房颤患者血小板最大聚集率的影响被引量：2

Effect of Dabigatran on Maximum Platelet Aggregation Rate of Patients with Nonvalvular Atrial Fibrillation

下载PDF

导出

摘要目的:探讨达比加群酯对非瓣膜性房颤患者血小板最大聚集率(MAR)的影响。方法:选择2016年3月至2017年5月沈阳医学院附属第二医院心内科收治的非瓣膜性房颤患者72例,随机分为达比加群酯组及华法林组,各36例。于用药前及用药10 d及30 d后应用PL系列多参数血小板功能分析仪,采用连续计数法原理,对血小板聚集功能进行检测。结果:无论以ADP还是AA作为诱导剂,达比加群酯组用药10、30 d后,MAR与用药前比较差异均无统计学意义(P>0.05);华法林组,用药10 d后,MAR有下降趋势,但差异无统计学意义(P>0.05),用药30 d后,MAR与用药前比较差异有统计学意义(P<0.05)。达比加群组与华法林组用药10、30 d后的MAR组间比较差异均无统计学意义。结论:达比加群酯与华法林均无增加MAR的趋势,与华法林比较,达比加群酯并不增加MAR。 Objective:To discuss the effect of Dabigatran on the maximum platelet aggregation rate(MAR)of patients with nonvalvular atrial fibrillation. Methods:A total of 72 patients with nonvalvular atrial fibrillation were collected from the cardiology department of the Second Hospital Affiliated to Shenyang Medical College from Mar 2016 to May 2017. They were divided into the Dabigatran group and the Warfarin group randomly,with 36 cases in each. MAR was detected before and at 10 days and 30 days after taking medicine by applying PL series multiple parameters of platelet function analyzer,and continuous counting method was adopted.Results:Whether ADP or AA were used as inducers,there was no significant difference in MAR in the Dabigatran group at 10 days and 30 days after treatment compared with before treatment(P>0.05). In the Warfarin group,there was a decline in MAR at 10 days(P>0.05)and 30 days(P<0.05)after treatment. There was no difference between the Darbiga group and the Warfarin group in MAR(P>0.05). Conclusions:Both Dabigatran and Warfarin do not have a tendency to increase MAR. Compared with Warfarin,Dabigatran does not increase MAR.

作者于淼李潞

机构地区沈阳医学院附属第二医院心内科

出处《沈阳医学院学报》 2017年第6期466-468,共3页 Journal of Shenyang Medical College

基金沈阳医学院科技基金项目(No.20142045)

关键词达比加群酯血小板最大聚集率非瓣膜性房颤 Dabigatran maximum platelet aggregation rate nonvalvular atrial fibrillation

分类号 R541.75 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献2

1吕超君,谭初兵,周植星,徐为人.新型口服抗凝药达比加群酯[J].中国新药与临床杂志,2012,31(3):113-116. 被引量：16
2张海澄,孙玉杰.美国心房颤动指南的最新更新——聚焦达比加群酯[J].中国心脏起搏与心电生理杂志,2011,25(3):278-279. 被引量：12

二级参考文献21

1Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation [ J ]. N Engl J Med, 2009, 361:1 139.
2Gage BF. Can we rely on RE-LY[J]? N Engl J Med, 2009,361:1 200.
3Connolly SJ, Ezekowitz MD, Yusuf S, et al. Newly identified events in the RE-LY trial[J]. N Engl J Med, 2010,363:1 875.
4Wann LS, Curtis AB, January CT, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation ( Updating the 2006 Guideline) [J]. Circulation, 2011,123 : 104.
5Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines far the Management of Patients with Atrial Fibrillation : a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines ( Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) [J]. Circulation, 2006,114 :e257.
6Wann LS, Curtis AB, Ellenbogen KA, et al. 2011 ACCF/AHA/ HRS focused update on the management of patients with atrial fibrillation (update on dabigatran) : a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines [ J ]. Circulation,2011 , 123 : 1144.
7van RYN J, STABGIER J, HAERTI'ER S, et al. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity[J]. Thromb Haemost, 2010, 103(6): 1116-1127.
8SORBERA LA, BOZZO J, CASTANER J. Dabigatran/dabiga- tran etexilate[J]. Drugs Future, 2005, 30.(9) : 877-885.
9HUGHES B. First oral warfarin alternative approved in the US[J]. Nat Rev Drug Diseov, 2010, 9(12): 903-906.
10CONNOLLY SJ, EZEKOWITZ MD, YUSUF S, et al. Dabigatran versus warfarin in patients with atrial fibrillation [J]. N Engl J Med, 2009, 361(12): 1139-1151.